Loading clinical trials...
Loading clinical trials...
A study to validate, in a prospective manner, the ability of the predefined Genomic Health bladder cancer assay to detect recurrence in patients undergoing surveillance for non-muscle invasive bladder...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Genomic Health®, Inc.
NCT05951179 · Non-muscle Invasive Bladder Cancer
NCT07206225 · Non-muscle Invasive Bladder Cancer
NCT07322263 · Bladder Cancer, Non-Muscle Invasive Bladder Cancer (NMIBC), and more
NCT06510374 · Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06245603 · Non-muscle Invasive Bladder Cancer
Institute for Prostate and Urologic Cancers - University of Minnesota
Minneapolis, Minnesota
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions